TARO News and Press, Taro Pharmaceutical Industries Ltd. From 07/13/22

Based on the current long-term trend, shares look like they will test long-term support. We expect support to hold there based on the company's strong earnings power and clean balance sheet. Adjusted cash flow numbers also remain strong. Investors may need to buy the fear here whe...

Taro Pharmaceutical press release (NYSE:TARO): Q4 GAAP EPS of $0.73. Revenue of $143.26M (-3.4% Y/Y). For further details see: Taro Pharmaceutical GAAP EPS of $0.73, revenue of $143.26M

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021 The qu...

Taro Pharmaceutical (NYSE:TARO) is scheduled to announce Q1 earnings results on Thursday, May 26th, after market close. The consensus EPS Estimate is $0.88 (+8.6% Y/Y) and the consensus Revenue Estimate is $147.01M (-0.9% Y/Y). Over the last 1 year, TARO has beaten EPS estimates 25% of the ti...

ADSK, AEO, COST, DELL, DOMO, FTCH, GPS, LGF.A, LIZI, MAXN, ME, MRVL, RRGB, SUMO, SVM, TARO, ULTA, VMW, WDAY, ZS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's close

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2022, after the close of market on Thursday, May 26, 2022. The release will be accessible on Taro’s website at www.taro.com . ...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today announced the completion of its acquisition of Alchemee, formerly The Proactiv Company (TPC), from Galderma. The acquisition includes Alchemee’s business and assets worldwide, including the Proactiv ...

Taro Pharmaceutical Industries (NYSE:TARO) will acquire Alchemee, formerly The Proactiv Company, from Galderma. The deal includes Alchemee’s business and assets around the world, including its flagship acne care brand Proactiv. Financial terms of the transaction have not been disclosed...

Alchemee’s flagship brand Proactiv® is an iconic product synonymous with acne care Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Alchemee, f...

The healthcare industry is growing rapidly amid increasing demand from an aging population and digital transformation in health systems and technologies, among other factors. And because clinical innovation is expected to continue in the healthcare sector this year, we think it could be profi...